Peginterferon alfa-2a is the first-line therapy of chronic hepatitis B (CHB) recommended by current treatment guidelines. 1-3 The advantages of peginterferon include a finite duration of therapy, higher rates of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) seroconversion and lack of anti-viral resistance. However, peginterferon alfa-2a is only effective in approximately one-
third of HBeAg-positive patients. [1] [2] [3] Thus, it is desirable to identify likely responders before the initiation of therapy to spare nonresponders from futile treatment.
In a recent issue of Alimentary Pharmacology and Therapeutics, Chan et al identified five baseline factors (age, sex, alanine aminotransferase ratio, HBsAg level and HBV DNA level) significantly associated with HBeAg seroconversion or HBeAg seroconversion with HBV DNA <2000 IU/mL (combined response) at 24 weeks posttreatment through multiple logistic regression analysis. They developed a scoring system with a score of 0-7 to predict the likelihood of response in genotype B-or C-infected HBeAg-positive Asian patients. 4 Patients with a baseline score of 0-1, 2-3, 4 and ≥5 had HBeAg seroconversion and combined response rates of 6.4% and 5.3%, 23% and 12.8%, 36.4% and 25% and 54.8% and 36.5%, respectively, at 24 weeks post-treatment. They further validated the predictive role of this scoring system in 519 patients with available data at 48 weeks post-treatment and demonstrated its comparable performance. The baseline score was also correlated with the likelihood of achieving HBsAg <20 000 IU/mL at 12 weeks of therapy.
Thus, the proposed scoring system is a convenient tool which assists clinicians in estimating the likelihood of sustained response to peginterferon alfa-2a and thereby select potential responders for treatment.
An important question that may affect the clinical usefulness of this scoring system is its ability to discriminate between two dis- HBeAg seroconversion with HBV DNA <2000 IU/mL from those who achieved HBeAg seroconversion with HBV DNA ≥2000 IU/mL to propose any additional on-treatment stopping rule to spare the latter patients from further treatment. A possible clue might be the relative abundance and distinct evolution of the precore or basal core promoter mutants among these patients. 5, 6 Further study is warranted to improve the predictive performance of this scoring system.
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L I N K E D C O N T E N T
Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients-same score, different outcomes. Author's Reply
We appreciate the comments that our baseline predictive score was not designed to differentiate patients who would have active or inactive viraemia after hepatitis B e antigen (HBeAg) seroconversion with peginterferon therapy. 1 However, the primary purpose of a baseline predictive score is to select the right patient for treatment, and our score can achieve this purpose.
Among patients who have a high predictive score, they have a higher chance to develop HBeAg seroconversion as well as a com- patients may have HBsAg >20 000 IU/mL at week 12, which has a high predictive value for nonresponse. 4 Nonetheless, even with ontreatment predictive biomarkers, it is impossible to accurately differentiate patients who will undergo HBeAg seroconversion with HBV DNA > 2000 IU/mL vs <2000 IU/mL posttreatment.
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